



# Invitation to the presentation of Gubra's Q1-2023 results

**Gubra will host a conference call for investors, analysts and media on Thursday, May 11, 2023, at 10:00am CET. The company's Q1-2023 Trading Statement will be published on the same day at 7:30am CET.**

The conference call will be hosted by the company's CEO Henrik Blou, CSO Niels Vrang and CFO Kristian Borbos. The presentation will be held in English. To participate in the conference call, please use the following dial-ins:

DK: +45 3274 0710

UK: +44 20 3481 4247

When dialling-in, please state the name of the call "Gubra Q1-2023 earnings release" or the conference ID: 3734401

The presentation can also be followed live via the link: <https://events.q4inc.com/attendee/322801355/guest>

It will be possible to listen to the presentation afterwards at the abovementioned link.

Presentation material for the conference call will be uploaded on [Gubra - Investor Relations](#) before the call.

## Contacts

Media: Sofia Pitt Boserup, [sbo@gubra.dk](mailto:sbo@gubra.dk), +45 4188 9586

Investors: Kristian Borbos, [kbo@gubra.dk](mailto:kbo@gubra.dk), +45 3080 8035

## About Us

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See [www.gubra.dk](http://www.gubra.dk) for more information.

## Attachments

[Invitation to the presentation of Gubra's Q1-2023 results](#)